Former Dendreon CEO Gold's New Cell Therapy Business Partners With Kite
This article was originally published in Scrip
With insights into what's needed to make a cell therapy for cancer succeed, former Dendreon Corp. CEO Mitchell Gold is shepherding new technology for closely-watched immunotherapies into the clinic through his latest company Alpine Immune Sciences Inc., which has entered into a $535m-plus partnership with Kite Pharma Inc.
You may also be interested in...
Mitchell Gold, who once led Dendreon, will lead the company, which obtains $90m in funding to bring forward three potential drug candidates for inflammatory conditions and cancer.
During a month when only two biotechnology companies have gone public, private drug developers continue to raise hundreds of millions of dollars in venture capital.
Private Company Edition: Recent VC financings across biopharma sectors include three major mega-rounds as Generate Biomedicines bringing in $370m, followed by $250m for Acelyrin and $125m for Chroma Medicine. Also, Treadwell raised a $91m series B and Ncardia brought in $60m-plus.